Protagonist Therapeutics ( (PTGX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Protagonist Therapeutics’ stock experienced notable movement due to a BMO Capital price target increase to $112, spurred by potential acquisition interest from Johnson & Johnson and the undervaluation of its assets, Rusfertide and Icotrokinra. However, the company’s quarterly net loss and insider selling activity have complicated the stock’s outlook, leading to a neutral market sentiment despite a strong buy consensus.
More about Protagonist Therapeutics
YTD Price Performance: 123.19%
Average Trading Volume: 947,438
Technical Sentiment Signal: Buy
Current Market Cap: $5.41B
For further insights into PTGX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.